Id: acc0926
Group: 2sens
Protein: CAMKII
Gene Symbol: CAMK2A
Protein Id: P11274
Protein Name: BCR_HUMAN
PTM: phosphorylation
Site: Thr286
Site Sequence: QPYQSIYVGGMMEGEGKGPLL
Disease Category: Cancer
Disease: Colorectal Cancer
Disease Subtype:
Disease Cellline: HT29
Disease Info:
Drug: DCA
Drug Info: "Deoxycholic acid (DCA): A secondary bile acid utilized as a pharmaceutical agent for localized fat reduction through adipocyte cytolysis, commonly employed in submental contouring. "
Effect: modulate
Effect Info: "Treatment of human colon cancer cells with DCA leads to phosphorylation of p - CAMKII and EGFR at the c - Src - dependent phosphorylation site Tyr84. Subsequently, this activation mediates the downstream activity of MAPK and the subsequent phosphorylation of ERK1/2, thereby promoting tumorigenesis."
Note:
Score: 4.0
Pubmed(PMID): 27086143
Sentence Index:
Sentence:

Sequence & Structure:

MVDPVGFAEAWKAQFPDSEPPRMELRSVGDIEQELERCKASIRRLEQEVNQERFRMIYLQTLLAKEKKSYDRQRWGFRRAAQAPDGASEPRASASRPQPAPADGADPPPAEEPEARPDGEGSPGKARPGTARRPGAAASGERDDRGPPASVAALRSNFERIRKGHGQPGADAEKPFYVNVEFHHERGLVKVNDKEVSDRISSLGSQAMQMERKKSQHGAGSSVGDASRPPYRGRSSESSCGVDGDYEDAELNPRFLKDNLIDANGGSRPPWPPLEYQPYQSIYVGGMMEGEGKGPLLRSQSTSEQEKRLTWPRRSYSPRSFEDCGGGYTPDCSSNENLTSSEEDFSSGQSSRVSPSPTTYRMFRDKSRSPSQNSQQSFDSSSPPTPQCHKRHRHCPVVVSEATIVGVRKTGQIWPNDGEGAFHGDADGSFGTPPGYGCAADRAEEQRRHQDGLPYIDDSPSSSPHLSSKGRGSRDALVSGALESTKASELDLEKGLEMRKWVLSGILASEETYLSHLEALLLPMKPLKAAATTSQPVLTSQQIETIFFKVPELYEIHKEFYDGLFPRVQQWSHQQRVGDLFQKLASQLGVYRAFVDNYGVAMEMAEKCCQANAQFAEISENLRARSNKDAKDPTTKNSLETLLYKPVDRVTRSTLVLHDLLKHTPASHPDHPLLQDALRISQNFLSSINEEITPRRQSMTVKKGEHRQLLKDSFMVELVEGARKLRHVFLFTDLLLCTKLKKQSGGKTQQYDCKWYIPLTDLSFQMVDELEAVPNIPLVPDEELDALKIKISQIKNDIQREKRANKGSKATERLKKKLSEQESLLLLMSPSMAFRVHSRNGKSYTFLISSDYERAEWRENIREQQKKCFRSFSLTSVELQMLTNSCVKLQTVHSIPLTINKEDDESPGLYGFLNVIVHSATGFKQSSNLYCTLEVDSFGYFVNKAKTRVYRDTAEPNWNEEFEIELEGSQTLRILCYEKCYNKTKIPKEDGESTDRLMGKGQVQLDPQALQDRDWQRTVIAMNGIEVKLSVKFNSREFSLKRMPSRKQTGVFGVKIAVVTKRERSKVPYIVRQCVEEIERRGMEEVGIYRVSGVATDIQALKAAFDVNNKDVSVMMSEMDVNAIAGTLKLYFRELPEPLFTDEFYPNFAEGIALSDPVAKESCMLNLLLSLPEANLLTFLFLLDHLKRVAEKEAVNKMSLHNLATVFGPTLLRPSEKESKLPANPSQPITMTDSWSLEVMSQVQVLLYFLQLEAIPAPDSKRQSILFSTEV

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
BCR DASATINIB Bcr/Abl fusion protein 4 - acute lymphoblastic leukemia DailyMed
DailyMed
BCR DASATINIB Bcr/Abl fusion protein 4 Unknown status acute lymphoblastic leukemia ClinicalTrials
BCR PONATINIB HYDROCHLORIDE Bcr/Abl fusion protein inhibitor 4 - acute lymphoblastic leukemia DailyMed
BCR IMATINIB MESYLATE Bcr/Abl fusion protein 4 - chronic myelogenous leukemia DailyMed
DailyMed
BCR IMATINIB MESYLATE Bcr/Abl fusion protein 4 Completed chronic myelogenous leukemia ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
BCR BOSUTINIB MONOHYDRATE Bcr/Abl fusion protein 4 - chronic myelogenous leukemia FDA
DailyMed
BCR PONATINIB HYDROCHLORIDE Bcr/Abl fusion protein inhibitor 4 - chronic myelogenous leukemia DailyMed
DailyMed
BCR NILOTINIB HYDROCHLORIDE MONOHYDRATE Bcr/Abl fusion protein 4 - chronic myelogenous leukemia DailyMed
BCR ASCIMINIB HYDROCHLORIDE Bcr/Abl fusion protein inhibitor 4 - chronic myelogenous leukemia FDA
BCR DASATINIB Bcr/Abl fusion protein 4 - chronic myelogenous leukemia DailyMed
DailyMed
BCR DASATINIB Bcr/Abl fusion protein 4 Completed chronic myelogenous leukemia ClinicalTrials
ClinicalTrials
BCR DASATINIB Bcr/Abl fusion protein 4 Recruiting chronic myelogenous leukemia ClinicalTrials
ClinicalTrials
ClinicalTrials
BCR DASATINIB Bcr/Abl fusion protein 4 Unknown status chronic myelogenous leukemia ClinicalTrials
BCR DASATINIB Bcr/Abl fusion protein 4 - neoplasm ATC
BCR ASCIMINIB Bcr/Abl fusion protein inhibitor 4 - neoplasm ATC
BCR DASATINIB Bcr/Abl fusion protein 4 - lymphoid leukemia EMA
BCR DASATINIB Bcr/Abl fusion protein 4 - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive EMA
BCR ASCIMINIB HYDROCHLORIDE Bcr/Abl fusion protein inhibitor 4 - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive EMA
BCR BOSUTINIB MONOHYDRATE Bcr/Abl fusion protein 4 - myeloid leukemia EMA
BCR IMATINIB Bcr/Abl fusion protein 3 Active, not recruiting acute lymphoblastic leukemia ClinicalTrials
ClinicalTrials
BCR IMATINIB Bcr/Abl fusion protein 3 Completed acute lymphoblastic leukemia ClinicalTrials
BCR PONATINIB Bcr/Abl fusion protein inhibitor 3 Active, not recruiting acute lymphoblastic leukemia ClinicalTrials
BCR PONATINIB Bcr/Abl fusion protein inhibitor 3 Recruiting acute lymphoblastic leukemia ClinicalTrials
BCR DASATINIB Bcr/Abl fusion protein 3 Active, not recruiting acute lymphoblastic leukemia ClinicalTrials
BCR DASATINIB Bcr/Abl fusion protein 3 Completed acute lymphoblastic leukemia ClinicalTrials
ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
CAMK2A-Thr286
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: